Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

Researchers have established that uveitis (a severe inflammatory eye disease) is bidirectionally linked to psoriatic ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...